Protalix BioTherapeutics, Inc. Form 8-K			
June 13, 2014			
UNITED STATES			
SECURITIES AND EXCHANGE COMMISSION			
Washington, D.C. 20549			
FORM 8-K			
CURRENT REPORT			
Pursuant to Section 13 or 15(d) of			
the Securities Exchange Act of 1934			
Date of Report (Date of Earliest Event Reported): June 13, 2014			
Date of Report (Date of Earliest Event Reported). June 13, 2014			
Protalix BioTherapeutics, Inc.			
(Exact name of registrant as specified in its charter)			

Florida (St. 4)	001-33357	65-0643773	
(State or other jurisdiction	(Commission File Number)	(IRS Employer	
of incorporation)	(00111111351011 1 110 1 (11111351)	Identification No.)	
2 Snunit Street Science Park, POB 455 Carmiel, Israel (Address of principal execu	20100 tive offices) (Zip Code)		
Registrant's telephone num	ber, including area code +97	2-4-988-9488	
(Former name or former address, if changed since last report.)			
** *	elow if the Form 8-K filing is i e following provisions (see Ger	ntended to simultaneously satisfy the filing obligation of neral Instruction A.2. below):	
"Written communications pu	rsuant to Rule 425 under the Se	ecurities Act (17 CFR 230.425)	
"Soliciting material pursuant	to Rule 14a-12 under the Exch	ange Act (17 CFR 240.14a-12)	
"Pre-commencement commu	nications pursuant to Rule 14d	-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
"Pre-commencement commu	nications pursuant to Rule 13e-	.4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 13, 2014, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing that David Aviezer, Ph.D., has decided to retire after almost 12 years from his role as the Company's President and Chief Executive Officer. He will retire this year upon the completion of a process to nominate his successor. In the meantime, Dr. Aviezer will continue serving as President and Chief Executive Officer and remains a member of the Board of Directors. A copy of the press release is filed as Exhibit 99.1.

## Item 9.01. Financial Statements and Exhibits

## (d) Exhibits

99.1 Press release dated June 13, 2014

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## PROTALIX BIOTHERAPEUTICS, INC.

Date: June 13, 2014 By: /s/ David Aviezer, Ph.D.

Name: David Aviezer, Ph.D.

Title: President and Chief Executive Officer